



US005489508A

United States Patent [19]

[11] Patent Number: **5,489,508**

West et al.

[45] Date of Patent: **Feb. 6, 1996**

[54] THERAPY AND DIAGNOSIS OF CONDITIONS RELATED TO TELOMERE LENGTH AND/OR TELOMERASE ACTIVITY

[75] Inventors: **Michael D. West**, Belmont, Calif.; **Jerry Shay**, Dallas; **Woodring Wright**, Arlington, both of Tex.

[73] Assignee: **University of Texas System Board of Regents**, Austin, Tex.

[21] Appl. No.: **38,766**

[22] Filed: **Mar. 24, 1993**

Related U.S. Application Data

[63] Continuation-in-part of Ser. No. 882,438, May 13, 1992, abandoned.

[51] Int. Cl.⁶ **C12Q 1/68**; C12P 19/34; C07H 21/04

[52] U.S. Cl. **435/6**; 435/15; 435/91.1; 435/91.5; 536/24.33; 436/64; 935/77

[58] Field of Search 435/6, 7.2, 91.1, 435/91.5, 15; 436/501, 34, 63, 64, 94; 935/77; 536/24.33

[56] References Cited

U.S. PATENT DOCUMENTS

4,737,454 4/1988 Dattagupta et al. 435/6

FOREIGN PATENT DOCUMENTS

9408053 4/1994 WIPO .

OTHER PUBLICATIONS

Harley, "Telomere Loss: Mitotic Clock or Genetic Time Bomb?" 256 *Nature* 271, 1991.

Yu et al., "Developmentally Programmed Healing of Chromosomes by Telomerase in Tetrahymena", 67 *Cell* 823, 1991.

Harley et al., "Telomeres Shorten During Ageing of Human Fibroblasts" 345 *Nature* 458, 1990.

Blackburn, "Structure and Function of Telomeres", 350 *Nature* 572, 1991.

Cech, "Ribozymes and Their Medical Implications", 260 *Jnl of Amer. Med. Assoc.* 3030, 1988.

Eck and Nabel, "Antisense oligonucleotides for therapeutic intervention", 2 *Current Opin. in Biotech* 897, 1991.

Zahler et al., "Inhibition of Telomerase by G-quartet DNA Structures", pp. 718-720, *Nature*, vol. 350, (Apr. 25, 1991).

Harley, *Mutation Research* (Nov. 1991) 256:271-282.

Counter et al., *EMBO J*, (May 5, 1992) 11:1921-1929.

Greider et al., (1991) *Molecular Cellular Biology* 11:4572-4580.

Blackburn et al. *Genome* (1989) 31:553-560.

Greider et al. (1987) *Cell* 51:887-898.

Greider and Blackburn, "A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis," *Nature* 337:331-337 (1989).

Cotten, "The in vivo application of ribozymes," *Trends in Biotechnology* 8:174-178 (1990).

Harley et al., "The Telomere Hypothesis of Cellular Aging," *Experimental Gerontology* 27:375-382 (1992).

Shay et al., "Loss of telomeric DNA during aging may predispose cells to cancer (Review)," *Int'l J. Oncology* 3:559-563 (1993).

Windle and McGuire, "Telomeres: the long and the short of it," *Proceedings of the American Association for Cancer Research* 33:594-595 (1992).

(List continued on next page.)

Primary Examiner—W. Gary Jones

Assistant Examiner—Carla Myers

Attorney, Agent, or Firm—Richard Warburg; Kevin Kaster; Amy Stark

[57] ABSTRACT

Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to inhibit telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity.

11 Claims, 14 Drawing Sheets

